Getty Images 468214585 Harvest fruit

We have built a portfolio of marketed products through partnerships and acquisition that are being delivered to patients in need across the world.

PIVLAZ

Pivlaz® is a potent, selective endothelin A (ETA) receptor antagonist indicated for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage (aSAH). Pivlaz® is commercially available in Japan for cerebral vasospasm following a successful launch in April 2022. Pivlaz® received marketing approval in South Korea in December 2023 with an expected launch in early 2025. Nxera owns the Japanese and APAC (ex-China) rights for Pivlaz®.

PIVLAZ®

Oravi

Hisamitsu Pharmaceutical Co.,Inc.

ORAVI® is a novel, once-daily mucoadhesive tablet formulation of the antifungal agent miconazole for the treatment of oropharyngeal candidiasis, a condition that occurs frequently in immunocompromised patients. ORAVI® is designed to deliver a sustained therapeutic concentration of miconazole directly to the infected site in the mouth. ORAVI was launched in Japan in 2019 and is marketed by Hisamitsu Pharmaceutical Co.,Inc. under an exclusive license from Nxera.

ORAVI®

Seebri Breezhaler

Novartis

An inhaled long-acting muscarinic antagonist (LAMA) indicated as a once-daily maintenance bronchodilator treatment to relieve symptoms of patients with COPD. Seebri® Breezhaler® was launched by Novartis in over 90 countries, including the EU, Japan and China. Nxera receives royalties on global product sales.

Seebri® Breezhaler®

Enerzair Breezhaler

Enerzair® Breezhaler® is a fixed dose, once daily combination of a long-acting muscarinic antagonist (LAMA), a long-acting beta agonist (LABA), and an inhaled corticosteroid (ICS) for treating asthma. Enerzair® Breezhaler® was launched by Novartis in Japan and the EU. Nxera is eligible to receive development milestones and receives royalties on global product sales.

Enerzair® Breezhaler®

Ultibro Breezhaler

A first-in-class, once-daily, inhaled fixed dose combination (LAMA/LABA) for treating COPD and launched by Novartis in over 90 countries, including the EU, Japan and China. Nxera receives royalties on global product sales.

Ultibro® Breezhaler®

These products continue to generate significant and stable revenues that enable further growth of our business.

Marketed Products

We have built a portfolio of marketed products through partnerships and acquisition that are being delivered to patients in need across the world.

PIVLAZ^®

PIVLAZ^®

ORAVI^®

ORAVI^®

Seebri^® Breezhaler^®

Seebri^® Breezhaler^®

Enerzair^® Breezhaler^®

Enerzair^® Breezhaler^®

Ultibro^® Breezhaler^®

Ultibro^® Breezhaler^®